Volume : 11, Issue : 01, January – 2024
Title:
DESIGN AND EVALUATION OF CLOFAZIMINE NANOCRYSTALS TO IMPROVE ITS ORAL BIOAVAILABILITY
Authors :
P. Venkatesh, D. Varun, S. K. Godasu, K. Janaki, P. Deepika
Abstract :
The aim of our project has been to develop formulation of Nanocrystals of an anti-leprotic drug Clofazimine, in order to improve its oral bioavailability. Clofazimine nanocrystals were prepared by anti-solvent precipitation method. In vitro data obtained for Clofazimine nanocrystals showed good entrapment efficiency and sustained drug release. From the results it can be concluded that the drug release from the nanocrystals were controlled by the surfactant tween 80. The solubility and in vitro dissolution studies suggested that the nanocrystal formulations can improve the bioavailability of the Clofazimine by improving its solubility and dissolution rate. The in-vitro diffusion studies were performed in phosphate buffer. tween 80 releases 90% of the drug within 3 hrs but in case of PVP and combination of PVP and tween 80, the release was extended to 4 hrs. PVP releases only 80% of drug in 4 hrs but combination of PVP and Tween formulations release maximum amount of drug i.e., 99% within 4 hrs. Hence, it was concluded that nano crystallization was a good approach to enhance the solubility and dissolution property of Clofazimine by nanoprecipitation technique and also sustained the drug release by using Tween 80 as surfactant and PVP as a stabilizer. Thus, nanocrystal drug delivery system can have adopted to increase the solubility and dissolution rate of poorly soluble drug like paclitaxel to enhance their bioavailability.
Key words: Formulation, Optimization, Clofazimine, Nanocrystals, Bioavailability
Cite This Article:
Please cite this article in press P. Venkatesh et al.,Design And Evaluation Of Clofazimine Nanocrystals To Improve Its Oral Bioavailability., Indo Am. J. P. Sci, 2024; 11 (01)
Number of Downloads : 10
References:
1. De Jong WH, Borm PJA. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3:133‐149. [PMC free article] [PubMed] [Google Scholar]
2. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198‐205. [PMC free article] [PubMed] [Google Scholar]
3. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113:151‐170. [PubMed] [Google Scholar]
4. Sonvico F, Mornet S, Vasseur S, et al. Folate‐conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconj Chem. 2005;16:1181‐1188. 10.1021/BC050050Z. [PubMed] [CrossRef] [Google Scholar]
5. Savjani KT, Gajjar AK, Savjani JK. Drug dsolubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. [PMC free article] [PubMed] [Google Scholar]
6. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15‐28. [PMC free article] [PubMed] [Google Scholar]
7. Junghanns J, Müller R. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008;3(3):295‐309. [PMC free article] [PubMed] [Google Scholar]
8. Tuomela A, Saarinen J, Strachan CJ, Hirvonen J. Production, applications and in vivo fate of drug nanocrystals. J Drug Deliv Sci Technol. 2016;34:21‐31. [Google Scholar]
9. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research . Waiver of in vivo bioavailability and bioequivalence studies for immediate‐release solid Oral dosage forms based on a biopharmaceutics classification system guidance for industry. Biopharmaceutics. 2017;1‐19. [Google Scholar]
10. Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in‐vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51‐66. [PubMed] [Google Scholar]
11. George J, Sabapathi SN. Cellulose nanocrystals: synthesis, functional properties, and applications. Nanotechnol Sci Appl. 2015;8:45‐54. [PMC free article] [PubMed] [Google Scholar]
12. Wang X, Zhuang J, Peng Q, Li Y. A general strategy for nanocrystal synthesis. Nature. 2005;437:121‐124. [PubMed] [Google Scholar]
13. Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23:534‐547. 10.1016/J.DRUDIS.2018.01.016. [PubMed] [CrossRef] [Google Scholar]
14. Lu Y, Chen Y, Gemeinhart RA, Wu W, Li T. Developing nanocrystals for cancer treatment. Nanomedicine. 2015;10:2537‐2552. [PubMed] [Google Scholar]
15. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top‐down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64‐75. [PubMed] [Google Scholar]
16. Boleininger J, Kurz A, Reuss V, Sönnichsen C. Microfluidic continuous flow synthesis of rod‐shaped gold and silver nanocrystals. Phys Chem Chem Phys. 2006;8:3824‐3827. [PubMed] [Google Scholar]
17. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62:1569‐1579. [PubMed] [Google Scholar]
18. Gao L, Liu G, Ma J, et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res. 2013;30:307‐324. [PubMed] [Google Scholar]
19. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Release. 2012;160:418‐430. [PubMed] [Google Scholar]
20. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water‐soluble drugs. Drug Discov Today. 2011;16:354‐360. [PubMed] [Google Scholar]
21. Brough C, Williams RO. Amorphous solid dispersions and nano‐crystal technologies for poorly water‐soluble drug delivery. Int J Pharm. 2013;453:157‐166. [PubMed] [Google Scholar]
22. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442‐453. [PMC free article] [PubMed] [Google Scholar]
23. Lee BK, Yun YH, Park K. Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci. 2015;125:158‐164. [PMC free article] [PubMed] [Google Scholar]
24. Lu Y, Li Y, Wu W. Injected nanocrystals for targeted drug delivery. Acta Pharm Sin B. 2016;6:106‐113. [PMC free article] [PubMed] [Google Scholar]
25. Merisko‐Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly‐water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63:427‐440. [PubMed] [Google Scholar]
26. Miao X, Yang W, Feng T, Lin J, Huang P. Drug nanocrystals for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;10:e1499 10.1002/wnan.1499. [PubMed] [CrossRef] [Google Scholar]
27. Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013;453:142‐156. [PubMed] [Google Scholar]
28. Peltonen L, Hirvonen J. Drug nanocrystals – versatile option for formulation of poorly soluble materials. Int J Pharm. 2018;537:73‐83. [PubMed] [Google Scholar]
29. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129‐139. [PubMed] [Google Scholar]
30. Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J Appl Toxicol. 2018;38:3‐24. [PMC free article] [PubMed] [Google Scholar]
31. Lu PS, Inbaraj BS, Chen BH. Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. J Sci Food Agric. 2018;98:51‐63. [PubMed] [Google Scholar]
32. Maudens P, Seemayer CA, Thauvin C, Gabay C, Jordan O, Allémann E. Nanocrystal‐polymer particles: extended delivery carriers for osteoarthritis treatment. Small. 2018;14:1703108 10.1002/smll.201703108. [PubMed] [CrossRef] [Google Scholar]
33. He Y, Xia DN, Li QX, Tao JS, Gan Y, Wang C. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation. Acta Pharmacol Sin. 2015;36:1151‐1160. [PMC free article] [PubMed] [Google Scholar]
34. Koshani R, Madadlou A. A viewpoint on the gastrointestinal fate of cellulose nanocrystals. Trends Food Sci Technol. 2018;71:268‐273. [Google Scholar]
35. Lu Y, Qi J, Dong X, Zhao W, Wu W. The in vivo fate of nanocrystals. Drug Discov Today. 2017;22:744‐750. [PubMed] [Google Scholar]
36. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R: Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012 Feb;67(2):290-8. doi: 10.1093/jac/dkr444. Epub 2011 Oct 20. (PubMed ID 22020137)
37. Peng-Fei-Yue ,Yu Li ,Jing Wan ,Youg Wang , Ming Yang ,Wei-Fong Zhu, Chang-Hong Vong , Hai Zong Yuah. Process optimization and evaluation of novel baicalin solid nanocrystals. International Journal of Nanomedicine.
38.Zahra Bastami, Azade Taheri1, Shahla Soltanpour2. Formulation, optimization and characterization of gemfibrozil nanocrystals prepared by wet milling technique. Asian Journal of Pharmaceutics – January-March 2015.
39. Huaxi Xiaoa, Tao Yanga, Qinlu Lina, ∗, Gao-Qiang Liua,∗, Lin Zhanga, Fengxiang Yub,Yuejiao Chena. Acetylated starch nanocrystals: Preparation and antitumor drug delivery study. International Journal of Biological Macromolecules 89 (2016) 456–464.